Archive December 21, 2021 Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive November 30, 2021 Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
Archive November 22, 2021 Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive November 5, 2021 Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study
Archive November 2, 2021 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
Archive October 26, 2021 Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021
Archive October 12, 2021 Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive October 7, 2021 Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Archive September 17, 2021 Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
Archive September 17, 2021 Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
